Aug 02, 2017 8:30am EDT Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference
Jul 17, 2017 8:30am EDT NEMUS Bioscience Announces NB2222 Pain and Anti-Addiction Data Accepted for Presentation at Upcoming Society of Neuroscience Meeting
Jul 11, 2017 8:30am EDT NEMUS Bioscience Provides Update on Previously Announced $20 Million Schneider Financing
Jun 22, 2017 5:30am EDT Nemus Bioscience Announces NB1111 Data Presentation at the 27th Annual Symposium of the International Cannabinoid Research Society (ICRS)
May 17, 2017 8:30am EDT Nemus Bioscience Reports Prodrug of Tetrahydrocannabinol (THC) Issued Patent Coverage in Canada and Hong Kong
May 09, 2017 8:30am EDT Nemus Bioscience Reports Prodrug of Tetrahydrocannabinol (THC) Receives Second Patent Issued in the United States Related to Proprietary Delivery Mechanisms for Treatment of Glaucoma
Mar 22, 2017 8:30am EDT NEMUS Bioscience and the University of Mississippi Announce Significant Anti-MRSA Synergy Data Utilizing Proprietary Cannabinoid-Based Anti-Infective Platforms
Mar 20, 2017 8:30am EDT Nemus Bioscience Signs Development Agreement with Nanomerics to Advance Ocular Formulation of NB1111 for the Treatment of Glaucoma Using Proprietary Molecular Envelope Technology (MET)
Mar 03, 2017 8:30am EST NEMUS Bioscience and Catalent to Advance NB1222 into Human Dosage Formulation Development
